These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://rebeccaqhbu337392.blogerus.com/60902036/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide